Cheno Effect on Transit in Health and IBS-C (Chenotransit)

Mayo Clinic

Status and phase: Completed; Phase 2

Conditions: Constipation-predominant Irritable Bowel Syndrome

Treatments: Drug: Sodium chenodeoxycholate (NaCDC); Other: Placebo

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00912301

1RC1DK086182 (U.S. NIH Grant/Contract)

08-001003

UL1RR024150 (U.S. NIH Grant/Contract)

R01DK079866 (U.S. NIH Grant/Contract)

R01DK054681 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).

Full description

Hypothesis: A hydrophobic di-alpha hydroxy bile salt, sodium chenodeoxycholate (CDC), delivered in a delayed release capsule to the ileocolonic region of the colon induces acceleration of colonic transit in patients with constipation-predominant IBS.

Methods: We shall study 36 patients with IBS-C, aged 18-65 years, and each treatment group will be balanced on gender and Body Mass Index (BMI) in the randomization. All patients will be assessed for symptoms of functional gastrointestinal disorder or psychological disturbance will be characterized in a standard fashion with questionnaires (Talley et al 1989), the Psychosomatic Symptom Checklist (SCL-90) and the Hospital Anxiety and Depression Inventory [HAD (Zigmond and Snaith 1983)]. With appropriate consent, a venous blood sample will be obtained from each participant for DNA extraction. Fasting Serum 7alpha-hydroxy-4-cholesten-3-one (7alpha-CHO) will be measured in all to ensure they do not have evidence of asymptomatic bile acid malabsorption. The normal range in our lab is <61 ng/mL.

Experimental design: A randomized, double blind, placebo controlled, dose-response parallel group design, with concealed allocation. Participants will undergo an initial baseline colonic transit for 24 hours to obtain Colonic Geometric Center (GC24). Sodium chenodeoxycholate (CDC) will be delivered to the ileocolonic region to assess ascending colon and whole colonic transit in participants with IBS-C; 12 participants per group will be randomized to placebo, 0.5 or 1 gram CDC each for a period of 4 days with the transit study conducted during the last 48 hours of drug ingestion. The CDC will be placed in gelatin capsules that are coated with methacrylate (EUDRAGIT-L®), a pH-sensitive polymer that will result in release of the active ingredient in the terminal ileum.

Experimental procedure: At standardized times (hourly for first 8 hours, and at 12, 24 and 48 h), dual gamma camera scans will be obtained to measure ascending colon and overall colonic transit. Patients will fill daily diaries to evaluate stool, frequency, consistency and ease of passage.

Gastrointestinal and Colonic Transit: A validated scintigraphic method to measure gastric, small bowel, and colonic transit will be used. A methacrylate-coated capsule dissolves in the alkaline pH of the distal ileum to release 111In-labeled activated charcoal particles to evaluate colonic transit on sequential scans. Meanwhile, orally ingested 99 mTc-labeled egg meal allows measurement of gastric and small bowel transit. (Technetium [99mTc] sestamibi (trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging.) We have previously shown that the gastric emptying (GE) at 2 and 4 hours, colonic filling (CF) at 6 hours, and colonic geometric center (GC, weighted average of isotopic counts) in colon at 4, 24 and 48 hours provide excellent summaries of gastric emptying and colonic transit with similar diagnostic accuracy as more detailed, costly, and time-consuming analyses. The normal values for these parameters have been previously published (Cremonini et al).

Scintigraphic gastric emptying and intestinal/colonic transit analysis: A variable region of interest program will be used to measure transit, as in previous studies from our lab. Radioisotope content in each region (gastric, ascending, transverse, descending, rectosigmoid) will be corrected for decay and tissue attenuation or depth.

Anticipated Result: CDC will accelerate whole colonic transit and loosen stool form in patients with constipation predominant IBS.

Enrollment: 36 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Healthy volunteers:

• Age (yr) 18-65
• Gender (F:M)3.5 :1
• Bowel Disease Questionnaire (BDQ) - IBS symptoms negative by Rome III criteria
• Hospital Anxiety/Depression score <8

IBS patients:

• Age (yr) 18-65
• Gender (F:M) 5 :1
• BDQ - IBS symptoms: positive by Rome III criteria
• Hospital Anxiety/Depression score: No restrictions

Exclusion criteria

• Abdominal surgery (except appendectomy or cholecystectomy)
• GI medications during the 48h prior to transit measurement
• Aspartate/Alanine transaminases >2 X Upper Limit of Normal (ULN)
• Other Medications except stable doses of estrogen, thyroid, low dose antidepressants of the dopaminergic or serotonergic class

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

36 participants in 3 patient groups, including a placebo group

NaCDC 500 mg

Experimental group

Description:

Participants randomized to this arm received 500 mg NaCDC per day for 4 days.

Treatment:

Drug: Sodium chenodeoxycholate (NaCDC)

NaCDC 1000 mg

Experimental group

Description:

Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.

Treatment:

Drug: Sodium chenodeoxycholate (NaCDC)

Placebo

Placebo Comparator group

Description:

Participants randomized to this arm received a placebo capsule each day for 4 days.

Treatment:

Other: Placebo